Company Overview

Sanofi Consumer Healthcare India Limited (SCHIL) | Scrip Code: 544250 (BSE), Symbol: SANOFICONR (NSE) | Document Dates: 4th June 2026 & 25th February 2026

Financial Performance Highlights (FY25)

Sanofi Consumer Healthcare India reported strong financial results for FY25 with revenue from operations growing 21% to ₹8,784 million (from ₹7,245 million in FY24) and net profit increasing 33% to ₹2,401 million (from ₹1,810 million in FY24). The company achieved a Return on Capital Employed of 62.5% and improved EBITDA margin to 36% from 34% in the previous year. Export contribution accounted for 19% of total turnover.

AGM and Corporate Governance

The company has convened its 3rd Annual General Meeting on 26th June 2026 through video conference to seek shareholder approval for several matters including adoption of financial statements, declaration of final dividend of ₹75 per share, re-appointment of Mr. Stanislas Camart as Director, and appointment of Price Waterhouse & Co as statutory auditors following the resignation of Kalyaniwalla & Mistry LLP. The board also seeks ratification of cost auditor remuneration.

Ownership and Structural Changes

The company completed its demerger from Sanofi India Limited effective June 1, 2024, pursuant to the Scheme of Arrangement approved by NCLT. This was followed by a mandatory open offer by CD&R Group (Opal Bidco SAS) resulting in a new shareholding pattern: Opella Healthcare Participations B.V. (60.40%), Opal Bidco SAS (10.87%), and public shareholders (28.73%). The company was listed on BSE and NSE effective September 13, 2024.

Dividend Distribution and Capital Structure

The company paid a final dividend of ₹55 per share for FY24 amounting to ₹1,267 million and has recommended a final dividend of ₹75 per share for FY25, subject to shareholder approval. The issued, subscribed, and paid-up equity share capital stands at ₹230 million (230,30,622 shares of ₹10 each) with reserves and surplus of ₹3,610 million.

Operational and Management Updates

The company employs 597 people with women representing 17.9% of permanent employees. Key management changes included the appointment of Mr. Richard D'souza as CFO effective 16th October 2025. The company maintains strong market position with Allegra and Combiflam products in the Top 300 Indian Consumer Healthcare market, serving 206 cities across India.

Regulatory Compliance and CSR

All statutory requirements under Companies Act, 2013 and SEBI Listing Regulations were complied with, and no material penalties were imposed by regulatory authorities. The company spent ₹48.55 million (2% of average net profit) on CSR initiatives including Project Amrit (clean drinking water) and Project Van Mitra (bamboo plantation).

Financial Position and Ratios

The company maintains a strong financial position with total assets of ₹5,137 million, cash and cash equivalents of ₹3,748 million, and a current ratio of 3.85. Key ratios include inventory turnover of 4.48 and net profit ratio of 0.27, reflecting efficient operations post-demerger.